ERIC 2022 | The role of MRD in clinical decision-making in R/R CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the clinical relevance of measurable residual disease (MRD) within the context of the IMPROVE trial (NCT04754035). In this study, patients with chronic lymphocytic leukemia (CLL) who did not achieve a deep response with venetoclax monotherapy were treated with venetoclax plus ibrutinib. Dr Scarfò considers MRD to be a powerful tool for the evaluation of response to treatment, but acknowledges that its full potential is yet to be reached. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
